Bioprocessing Antibody Drug Conjugates in Biopharma: Making Magic Bullets

Article   Mar 28, 2017 | Original Article by Adam Tozer Ph.D

 
Bioprocessing Antibody Drug Conjugates in Biopharma: Making Magic Bullets

ADCs are the next generation of cancer therapies. Credit: Lonza

 
 
 
 

RELATED ARTICLES

Zika Virus Persists in Brain and Lymph Tissue for up to 72 Days

Article

Study using Rhesus monkeys describes how the Zika virus can hide from the body's immune system in brain and lymph tissue for up 72 days. And also describes the possible mechanism by which Zika causes microcephaly in gestating babies.

READ MORE

Single-Use Technologies in Bioprocessing: How Far Can They Go?

Article

Single-use, disposable equipment in the biopharmaceutical manufacturing is indelible and wide-ranging. This article discusses the future directions and limitations with regards to implementation of this technology.

READ MORE

Managing the Genomics Data Deluge

Article

With such tremendous amounts of data bring produced, adequate storage capacity and methodology will be crucial for the advancement of genomic research and medicine.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE